Freedom of Information

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):
• Avelumab + Axitinib
• Axinitib
• Cabozantinib
• Everolimus
• Lenvantinib + Everolimus
• Nivolumab monotherapy
• Nivolumab + Cabozantinib
• Nivolumab + Ipilimumab
• Pazopanib
• Pembrolizumab monotherapy
• Pembrolizumab + Lenvatinib
• Pembrolizumab + Axitinib
• Radiotherapy only
• Sunitinib
• Temsirolimus
• Tivozanib
• Other active systemic anti-cancer therapy
• Palliative care only

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage)
• Cobimetinib
• Dabrafenib
• Dabrafenib + Trametinib
• Dacarbazine
• Denosumab
• Encorafenib + Binimetinib
• Ipilimumab monotherapy
• Ipilimumab + Nivolumab
• Nivolumab monotherapy
• Nivolumab + Relatlimab
• Pembrolizumab
• Trametinib
• Vemurafenib
• Vemurafenib + Cobimetinib
• Other active systemic anti-cancer therapy
• Palliative care only

Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:
• Ipilimumab monotherapy
• Ipilimumab + Nivolumab
• Nivolumab monotherapy
• Nivolumab + Relatlimab
• Pembrolizumab
• Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
• Other active systemic anti-cancer therapy
• Palliative care only